Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing Remitting Multiple Sclerosis (RRMS)”

184 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 184 results

Large-scale testing (Phase 3)Not Yet RecruitingNCT07189325
What this trial is testing

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)Anti-CD20 Therapy
University Hospital, Montpellier 250
Early research (Phase 1)Study completedNCT01738347
What this trial is testing

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

Who this might be right for
Relapsing-remitting Multiple Sclerosis (rrMS)
GE Healthcare 30
Testing effectiveness (Phase 2)Study completedNCT01717664
What this trial is testing

Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing Remitting Multiple Sclerosis
RedHill Biopharma Limited 18
Large-scale testing (Phase 3)Study completedNCT03093324
What this trial is testing

A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 506
Testing effectiveness (Phase 2)UnknownNCT01466114
What this trial is testing

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Who this might be right for
Relapsing-remitting Multiple SclerosisSecondary-progressive Multiple SclerosisPrimary-progressive Multiple Sclerosis
University of California, Los Angeles 64
Large-scale testing (Phase 3)Study completedNCT02637856
What this trial is testing

Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Genentech, Inc. 608
Early research (Phase 1)Ended earlyNCT01144351
What this trial is testing

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Elan Pharmaceuticals 32
Post-approval studies (Phase 4)Study completedNCT02019550
What this trial is testing

Rebif® Rebidose® Versus Rebiject II® Ease-of-Use

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
EMD Serono 97
Large-scale testing (Phase 3)Study completedNCT00360906
What this trial is testing

Omega-3 Fatty Acid Treatment in Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Haukeland University Hospital 100
Large-scale testing (Phase 3)WithdrawnNCT01941004
What this trial is testing

Safety and Efficacy of Fingolimod in MS Patients in China

Who this might be right for
Multiple Sclerosis (Relapsing Remitting)
Novartis Pharmaceuticals
Not applicableStudy completedNCT01626248
What this trial is testing

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

Who this might be right for
Multiple Sclerosis
John F. Foley, MD 164
Testing effectiveness (Phase 2)Study completedNCT00640328
What this trial is testing

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

Who this might be right for
Multiple Sclerosis
GlaxoSmithKline 38
Testing effectiveness (Phase 2)Study completedNCT02410200
What this trial is testing

Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Biogen 22
Large-scale testing (Phase 3)Study completedNCT00509145
What this trial is testing

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis
Teva Branded Pharmaceutical Products R&D, Inc. 1,106
Not applicableActive Not RecruitingNCT07497126
What this trial is testing

The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis (RRMS)Malnutrition or Risk of Malnutrition
Antalya Training and Research Hospital 169
Not applicableStudy completedNCT01804647
What this trial is testing

Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease

Who this might be right for
Multiple Sclerosis (MS)Relapsing-Remitting MSPrimary Progressive MS+2 more
GeNeuro Innovation SAS 58
Testing effectiveness (Phase 2)Study completedNCT01051817
What this trial is testing

POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler

Who this might be right for
Relapsing-remitting Multiple SclerosisRRMS
Novartis Pharmaceuticals 73
Testing effectiveness (Phase 2)Looking for participantsNCT07510607
What this trial is testing

Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis

Who this might be right for
Multiple SclerosisRRMSRelapsing Remitting MS
Ari Green 40
Not applicableStudy completedNCT02677077
What this trial is testing

Clinical Disease Activity With Long Term Natalizumab Treatment

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 277
Testing effectiveness (Phase 2)Ended earlyNCT01134627
What this trial is testing

Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 305
Load More Results